DV
Dividend Vision

EIKN — Eikon Therapeutics, Inc. Common Stock

Eikon Therapeutics, Inc. Common Stock (EIKN)

Total return is -26.3% over the past 0.5 years, 41.5 points behind SPY at 15.2%.

Eikon Therapeutics is a clinical biopharmaceutical company developing medicines for serious unmet medical needs, including immuno-oncology and cancer treatments targeting pathways such as TLR7/8, PARP1, WRN helicase, and androgen receptor variants. The company does not currently distribute dividends. Eikon appeals to investors seeking exposure to early-stage biotech development rather than current income, as the company is in clinical stages with multiple pipeline candidates.

EIKN key facts

Asset type
Stock
Asset class
Equity
Inception date
02/05/2026
Last close
$11.05
Market cap
$528,934,432
Average volume
637720.0
Payout ratio
0.0
Forward P/E
0.0
EPS
$-6.32